Peter Humphrey v. GlaxoSmithKline PLC

905 F.3d 694
CourtCourt of Appeals for the Third Circuit
DecidedSeptember 26, 2018
Docket17-3285
StatusPublished
Cited by17 cases

This text of 905 F.3d 694 (Peter Humphrey v. GlaxoSmithKline PLC) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Peter Humphrey v. GlaxoSmithKline PLC, 905 F.3d 694 (3d Cir. 2018).

Opinion

McKEE, Circuit Judge

Section 1964(c) of the Racketeer Influenced and Corrupt Organizations Act ("RICO"), 18 U.S.C. §§ 1961 - 1968, creates a private right of action for a plaintiff that "is injured in his [or her] business or property" as a result of conduct that is proscribed by the statute. In RJR Nabisco, Inc. v. European Community , the Supreme Court determined that, although a litigant may file a civil suit against parties for racketeering activity committed abroad, § 1964(c)'s private right of action is only available to a litigant that can "allege and prove a domestic injury to its business or property." 1

In this case of first impression for this court, we must decide whether Plaintiffs pled sufficient facts to establish that they suffered a domestic injury under § 1964(c). For the reasons that follow, we will affirm the District Court's judgment that they have not.

I.

A. Factual Background

Plaintiffs Peter Humphrey and Yu Yingzeng are co-founders of ChinaWhys, an investigations firm that assists foreign companies doing business in China with American anti-bribery regulations compliance. Although Plaintiffs resided in Beijing during the events alleged in their complaint, much of ChinaWhys' business was conducted with American companies.

Plaintiffs allege that Defendants, GlaxoSmithKline plc ("GSK PLC") and GlaxoSmithKline LLC ("GSK LLC"), engaged in widespread bribery in China in order to obtain improper commercial advantages and that they did so with the approval of Mark Reilly. Reilly was the Chief Executive Officer of GlaxoSmithKline Investment Co., Ltd. ("GSK China"). GlaxoSmithKline is a multinational healthcare company that has offices in England and the United States. Sometime in 2011, a whistleblower who had worked for Defendants sent Chinese regulators correspondence accusing GlaxoSmithKline of bribery. Those allegations of corruption included a claim that GSK China maintained a policy of paying off doctors to *697 increase sales. Thereafter, Defendants tried to uncover the whistleblower's identity.

As part of the ensuing inquiry, Humphrey and Yingzeng met with Reilly and other members of GSK China's senior management in GSK China's Shanghai office to discuss GlaxoSmithKline's internal investigation into the source of the whistleblower reports. According to Plaintiffs, GSK China representatives told ChinaWhys that it believed Vivian Shi, a GSK China employee who had been fired, orchestrated a "smear campaign" against GlaxoSmithKline by falsely accusing the pharmaceutical company of engaging in corrupt practices. ChinaWhys agreed to conduct a background investigation of Shi in what Plaintiffs describe as an attempt to limit the "efficacy of her extortion." 2 The details of that understanding were memorialized in a "Consultancy Agreement." 3 That agreement provided that, among other things, the arrangement was to be governed by Chinese law and that all disputes arising out of, or in connection to, it were subject to arbitration in China. 4

GlaxoSmithKline later learned of additional whistleblower emails and GSK China asked ChinaWhys to also identify the source of those communications. In addition, GSK China personnel asked ChinaWhys to investigate certain Chinese agencies to find out who was conducting the investigation into GSK China's alleged misconduct.

In July 2013, Plaintiffs were arrested when police raided ChinaWhys' Shanghai office and Plaintiffs' Beijing home. The arrests resulted in Plaintiffs' conviction and imprisonment. They were deported from China upon their release from prison.

Reilly was subsequently convicted of bribing physicians and was also imprisoned and deported from China upon his release. The Chinese government fined GSK PLC $492 million for its bribery practices in the region, and GSK PLC entered a settlement agreement with the United States Securities Exchange Commission.

Plaintiffs brought this suit in the United States District Court, alleging, inter alia , RICO claims and pendent state law claims. GSK China was not named as a party. 5 Plaintiffs contend that their business was "destroyed and their prospective business ventures eviscerated" as a result of Defendants' misconduct. 6 They also contended that "GSK officials" knew that the accusations of corruption were true and that the bribery had been carried out at Reilly's direction.

Defendants moved to compel arbitration, or, in the alternative, to dismiss the complaint for lack of subject-matter jurisdiction. They argued that subject-matter jurisdiction was lacking because, even though Plaintiffs may have had numerous clients in the United States, their alleged injuries were foreign because Plaintiffs'

*698 business was in China, their only offices were in China, no work was done outside of China, Plaintiffs resided in China, and because any destruction of Plaintiffs' business occurred while Plaintiffs were imprisoned in China by Chinese authorities. The District Court agreed and granted Defendants' motion to dismiss. This timely appeal followed.

B. Legal Background

RICO "creates a private civil cause of action that allows '[a]ny person injured in his business or property by reason of a violation of section 1962 to sue in federal district court ...." 7 A successful plaintiff may "recover threefold the damages. ..." 8

RICO is implicated when defendants have engaged in a "pattern of racketeering activity." 9 That pattern consists of certain statutorily defined predicate acts "encompass[ing] dozens of state and federal offenses" "that together demonstrate the existence or threat of continued criminal activity." 10 The statute "sets forth four specific prohibitions aimed at different ways in which a pattern of racketeering activity may be used to infiltrate, control, or operate a[n] enterprise['s]" criminal misconduct. 11 Plaintiffs allege that Defendants violated two of those prohibitions-§§ 1962(c) and (d). Section 1962(c) proscribes participating in the conduct of an interstate enterprise's affairs through a "pattern of racketeering activity," 12 which RICO defines as "at least two acts of racketeering activity." 13

Free access — add to your briefcase to read the full text and ask questions with AI

Related

OJO v. CHARLES
D. New Jersey, 2025
Percival Partners Limited v. Paa Nduom
99 F.4th 696 (Fourth Circuit, 2024)
Yegiazaryan v. Smagin
599 U.S. 533 (Supreme Court, 2023)
Humphrey, P. v. GlaxoSmithKline PLC
2021 Pa. Super. 180 (Superior Court of Pennsylvania, 2021)
Berezkina v. Finnair
N.D. Illinois, 2020
Nuevos Destinos, LLC v. Peck
D. North Dakota, 2019
Martin Hilti Family Trust v. Knoedler Gallery, LLC
386 F. Supp. 3d 319 (S.D. Illinois, 2019)
RamiroAviles v. S&P Global, Inc.
380 F. Supp. 3d 221 (S.D. Illinois, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
905 F.3d 694, Counsel Stack Legal Research, https://law.counselstack.com/opinion/peter-humphrey-v-glaxosmithkline-plc-ca3-2018.